Background: Cerebral blood volume (CBV) mapping with a dynamic susceptibility contrast (DSC) perfusion technique has become a clinical tool in diagnosing and follow-up of brain tumors. Ferumoxytol, a long-circulating iron oxide nanoparticle, has been tested for CBV mapping, but the optimal dose has not been established. Purpose: To compare ferumoxytol DSC of two different doses to standard of care gadoteridol by analyzing timeintensity curves and CBV maps in normal-appearing brain regions. Study Type: Retrospective. Subjects: Fifty-four patients with various brain disorders. Field Strength/Sequence: 3T MRI. DSC-MRI was performed with 0.1 mmol/kg gadoteridol and 1 day later with ferumoxytol in doses of 1 or 2 mg/kg. Assessment: Signal changes during first pass, relative CBV (rCBV) in normal-appearing thalamus, putamen, and globus pallidus, and contrast-to-noise ratio (CNR) of the CBV maps were compared between gadoteridol and various doses of ferumoxytol using an automated method. To subjectively assess the quality of the CBV maps, two blinded readers also assessed visual conspicuity of the putamen. Statistical Tests: Linear mixed effect model was used for statistical comparison. Results: Compared to gadoteridol, 1 mg/kg ferumoxytol showed no difference in CNR (P 5 0.6505), peak DR2*, and rCBV in the putamen (P 5 0.2669, 0.0871) or in the thalamus (P 5 0.517, 0.9787); 2 mg/kg ferumoxytol increased peak DR2* as well as the CNR (P < 0.0001), but also mildly increased rCBV in putamen and globus pallidus (P 5 0.0005, 0.0012). Signal intensities during first pass remained highly above the noise level, with overlapping of 95% confidence intervals with noise only in 3 out of 162 tested regions. Compared to gadoteridol, the visual image quality showed mild improvement with 1 mg/kg (P 5 0.02) and marked improvement with 2 mg/kg ferumoxytol (P < 0.0001). Data Conclusion: 1 mg/kg ferumoxytol provides similar imaging results to standard gadoteridol for DSC-MRI, and 2 mg/kg has a benefit of increased CNR, but may also result in mildly increased rCBV values.
D
ynamic susceptibility contrast (DSC) magnetic resonance imaging (MRI) perfusion technique is the most commonly applied perfusion MRI technique in clinical practice, 1, 2 and gaining increasing importance in follow-up of brain tumors. 3, 4 A large body of literature is available using DSC-derived cerebral blood volume (CBV) maps with gadolinium to differentiate true tumor progression from treatment-related inflammatory changes, called pseudoprogression, which may be indistinguishable on anatomical MR images. 5 While the accuracy of DSC perfusion and CBV calculation is relatively high within an institution, the threshold CBV values to differentiate high vs. low vascularity may vary widely between institutions. 5 DSC uses repeated acquisitions of rapid T 2 *-weighted images to track signal intensity changes as a short bolus of contrast agent passes through the brain. Gadolinium-based contrast agents (GBCA) are most often used, as these exhibit sufficient T 2 * effects at high concentrations. GBCAs are generally safe, and nephrogenic systemic fibrosis (NSF) remains a very rare complication. 6, 7 For DSC, GBCAs are far from optimal agents, as the contrast agent leaks into the interstitial space and produces unwanted T 1 effects which confound the ideally T 2 *-weighted DSC signal. Therefore, various advanced processing and leakage correction methods are proposed, which often contribute to the variability of results. 8 In addition, gadolinium deposition in the deep gray matter structures is a recently described concern, although its clinical impact is still unknown. 9, 10 Therefore, there is a clinical need in exploring alternative contrast agents.
11
Iron-based contrast agents are viable alternatives. Ferumoxytol is a macromolecular, carbohydrate-coated iron oxide particle, which has been extensively studied as an MRI contrast agent. 12 Ferumoxytol is marketed as Feraheme for iron replacement in adult patients with renal failure, and is sometimes used off-label as an MRI agent. Blood pool distribution early after injection is beneficial in imaging the intravascular space. [13] [14] [15] [16] [17] Ferumoxytol has been tested in cerebral DSC perfusion imaging, showing great potential in differentiating progression from pseudoprogression with the advantage that leakage correction is unnecessary. 18, 19 Still, the effect of various ferumoxytol doses on time-intensity curves, CBV maps, and relative CBV (rCBV) values compared to gadolinium is unknown. Establishing an optimal ferumoxytol dose for DSC is relevant both clinically and scientifically, and may help standardizing CBV mapping as a true intravascular agent. The purpose of this study was to compare ferumoxytol DSC with two different doses to gadolinium DSC by analyzing time-intensity curves and CBV maps in normalappearing brain regions.
Materials and Methods

Subjects
This study reviewed 54 subjects (36 males, 18 females, mean age 6SD 53.65 6 14.26 years) with focal cerebral pathologies to evaluate perfusion imaging in normal-appearing brain regions. Out of 54 subjects, 34 had brain tumors (22 glioblastomas, three highgrade gliomas, three low-grade gliomas, one ependymoma, one pituitary adenoma, and four metastases), and 20 subjects had nontumoral disorders (stroke, multiple sclerosis, cavernoma, other vascular lesions). All subjects gave informed consent and were enrolled in one of four Institutional Review Board-approved imaging protocols (clinicaltrials.gov identifiers: NCT00659776, NCT00660543, NCT00659126, NCT00769093). These protocols were common in study design, including MR perfusion imaging using gadoteridol (ProHance, Bracco Diagnostic, Princeton, NJ) on day 1, and using ferumoxytol (Feraheme, AMAG Pharmaceuticals, Cambridge, MA) on day 2. Subjects were enrolled in this analysis if evaluable MR sequences including anatomical scans, DSC perfusion with gadolinium, and ferumoxytol were available. In longitudinal studies only the first imaging timepoint was included in this analysis. All subjects had a glomerular filtration rate higher than 50 ml/min/1.73m 2 .
Contrast Agents
Contrast agents were injected using a dual syringe power injector, (Medrad, Spectris Solaris, Bayer Healthcare, Whippany, NJ) with the first syringe filled with contrast agent, and the second with saline. Gadoteridol was administered using the 0.1 mmol/kg standard dose. Ferumoxytol was given either in a 2 mg/kg dose (17 subjects), or as a total dose of 75 mg (37 subjects), depending on the protocol. The latter group was considered a 1 mg/kg dose ferumoxytol group (mean ferumoxytol dose per body weight 6SD: 0.91 6 0.23 mg/kg). Ferumoxytol was 1:1 diluted with normal saline, resulting in 15 mg/ml iron concentration.
To evaluate for potential saturation of peak amplitude during first pass, dose was also expressed as mg injected contrast agent per total circulating blood volume estimated using Nadler et al's formula 
where Ht denotes the height in meters, and Wt is the body weight in kilograms.
MRI
All MRI scans were performed on an US Food and Drug Administration (FDA)-approved 3T scanner (TIM Trio, Siemens, Erlangen, Germany) using a 12-channel receive-only head coil. 
mm gap). Each
Journal of Magnetic Resonance Imaging contrast agent was injected as a bolus with a flow rate of 3 ml/s, followed by 20-ml saline flush with the same flow rate.
Image Processing
CALCULATION OF PERFUSION MAPS. DSC scans were processed on an offline workstation using NordicICE (v. 2.3, NordicNeuroLab, Bergen, Norway), a dedicated processing software. To evaluate peak DR2* caused by the contrast bolus, a prebolus (DSC pre ) image and an image with the lowest signal intensity (DSC min ) during the first pass (based on a slice through the basal ganglia) were extracted for analysis (Fig. 1A) . DR2*-time curves were used for further processing, which is assumed to be proportional with the tracer concentration (Fig. 1B,C) . After motion correction, CBV maps were calculated as the area under the DR2*(t) curve. No temporal or spatial smoothing was used to limit any potential confounding effect on the data. Gadoteridol-derived CBV maps, calculated with a standard leakage-correction method 21, 22 and ferumoxytol-derived CBV maps without leakage correction were produced.
COREGISTRATION. DSC pre scans were coregistered to the anatomical T 1 -weighted MPRAGE images with 6 degrees-of-freedom linear fit, correlation ratio cost function, and trilinear interpolation using FSL FMRIB's Linear Image Registration Tool (FLIRT). 23 Then the transformation matrix of the CBV-to-MPRAGE coregistration was used to align the CBV maps and DSC min image sets to the MPRAGE space (trilinear interpolation). Coregistration was visually inspected in each individual MRI set.
VOLUME OF INTEREST (VOI) PLACEMENT.
Three normalappearing subcortical structures, the thalamus, globus pallidus, and putamen, were segmented on T 1 -weighted MPRAGE images with an automatic algorithm using FMRIB's Integrated Registration & Segmentation Tool (FIRST). 24 All automatically segmented VOIs were visually inspected to manually exclude any abnormalappearing regions based on T 2 -weighted images. Normal-appearing white matter VOIs were prescribed manually in the frontal and occipital regions and in the centrum semiovale using MIPAV (Medical Image Processing, Advanced Visualization, v. 6.01, National Institutes of Health, mipav.cit.nih.gov/). 25 Figure 2 illustrates VOIs. VOIs were applied on all coregistered CBV maps, DSC pre , and DSC min image sets.
PEAK DR2*, CNR AND rCBV CALCULATION. DSC pre and DSC min image sets were used to calculate Peak DR2* in each VOI using the formula:
in which SI pre and SI min indicate the mean signal intensities on DSC pre and DSC min images, TE is the echo time. 26 CNR of CBV maps was calculated in the putamen because it is a fairly homogenous structure, and has clearly higher rCBV than the white matter. CNR was calculated using the formula:
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where l indicates the mean CBV value and r is the standard deviation of CBV value in the corresponding VOIs on the CBV maps. 27 Relative CBV values were obtained by dividing the mean CBV values of the thalamus, globus pallidus, and putamen by mean CBV in white matter.
VISUAL ASSESSMENT OF CBV MAPS. Anonymized CBV map pairs, obtained with gadolinium and ferumoxytol, coregistered to MPRAGE image, were read by two independent readers (C.V., and A.H., with 15 and 5 years of experience in image analysis, respectively). Readers were blinded to contrast agent information. Conspicuity of the putamen was evaluated using a three-point scale scoring system: 1 (poor conspicuity): difficult to identify the putamen; 2 (moderate conspicuity): the putamen can be identified, but appears heterogeneous; 3 (good conspicuity): putamen is well identified as a fairly homogeneous structure.
Statistical Analysis
Peak DR2*, CNR, and rCBV values in all normal-appearing brain region VOIs, visual conspicuity of the putamen were compared among gadoteridol, 1 mg/kg, and 2 mg/kg ferumoxytol doses using a linear mixed effects model with adjustment for multiple comparisons using the Tukey-Kramer method. In order to determine whether the signal dropout caused by a high dose of ferumoxytol reaches a noise level, the 95% confidence intervals (CIs) of the mean minimal signal intensities during the first pass of ferumoxytol at various doses and the 95% CI of the image noise were qualitatively compared. P < 0.05 was considered statistically significant. All analyses were performed using SAS 9.2 (SAS Institute, Cary, NC).
Results Table 1 presents the mean peak DR2* and mean rCBV values in deep gray matter structures with gadoteridol and with two different doses of ferumoxytol.
Peak DR2* Peak DR2* was not significantly different between 1 mg/kg ferumoxytol and gadoteridol in any of the investigated regions (P > 0.05) (Fig. 3A) . On the other hand, DR2* values were higher with 2 mg/kg ferumoxytol (P < 0.0001).
rCBV The 1 mg/kg dose of ferumoxytol provided similar rCBV values to gadoteridol, without significant difference in the putamen or thalamus (P 5 0.0871 and P 5 0.9787, respectively) and minimal difference in the globus pallidus (P 5 0.0204) (Fig. 3B) . Two mg/kg ferumoxytol provided mildly higher rCBV values both in the globus pallidus and putamen compared to gadoteridol (P 5 0.0012 and P 5 0.0005, respectively) or compared to 1 mg/kg ferumoxytol (P < 0.0001). In the thalamus, rCBV values were not significantly different between contrast agents (2 mg/kg ferumoxytol vs. gadoteridol: P 5 0.7453) and ferumoxytol doses (P 5 0.3600).
Minimal Signal Intensities
Noise level was 15.8 6 3.2 (mean 6 SD), based on measurements from the four corners of 10 DSC images from different subjects. The mean minimal signal intensities during the first pass of ferumoxytol remained highly above the noise level for any time-course data even with 2 mg/kg ferumoxytol dose (Fig. 4) . Only three VOIs (all in the thalamus) out of the 162 VOIs (thalamus, putamen, globus pallidus in 54 subjects) yielded 95% CIs that overlapped with the 95% CI of the noise.
CNR
Differences of CNR values in normal-appearing deep gray matter structures with gadoteridol and ferumoxytol with two different doses are presented in Fig. 5A . CNR in the putamen was similar between 1 mg/kg ferumoxytol and 
Visual Assessment of CBV Maps
The two independent readers, blinded to contrast agent information, evaluated the conspicuity of putamen ( Fig. 6 ) with overall weighted kappa of 0.54 (SE 0.07), indicating moderate agreement. 28 Assessment of ferumoxytol CBV maps showed good agreement with weighted kappa of 0.64 (0.09), while gadolinium CBV maps were read with fair interrater agreement with weighted kappa of 0.39 (0.11). Averaged scores of visual assessment of the two readers were 2.16 (0.07) with gadolinium and mildly increased to 2.42 (0.08) with 1 mg/kg ferumoxytol (P 5 0.02), and markedly increased to 2.83 (0.12) with 2 mg/kg ferumoxytol (P < 0.0001) (Fig. 5B ).
Discussion
Perfusion-weighted MRI may provide additional information in cerebrovascular diseases, as well as in brain tumors.
There is a substantial variability in available image acquisition techniques, postprocessing methods, and contrast agent administration protocols. Intravascular, blood pool contrast agents are theoretically beneficial when assessing the intravascular space, since imaging changes arise only from tracer inside the vessels. Ferumoxytol DSC MRI has been explored in earlier studies and showed benefit over gadolinium-based contrast agents in the assessment of tumor blood volume. 18, 19 This study revealed that 1 mg/kg of 1:1 diluted ferumoxytol bolus is equivalent to 0.1 mmol/kg gadolinium bolus injected at a 3 ml/sec flow rate: signal changes during first pass, rCBV values, and CNR are essentially the same. Normal-appearing cerebral structures are often used when comparing techniques. 29, 30 The method applied in the current study aimed to minimize observer bias, by using automated segmentation of the deep gray matter structures, which was applied to both ferumoxytol and gadolinium DSC maps. The white matter selection based on a T 1 -weighted MPRAGE image was the only manual step, and these VOIs were applied on both CBV maps without further manual adjustments. With administration of higher doses of paramagnetic contrast agent, signal intensities may reach a noise level that results in biased CBV values. 31 Therefore, in this study we investigated the minimal signal intensities during the first pass of ferumoxytol with different doses. Even in the higher 2 mg/kg dose group, signal intensities remained highly above the noise level, with overlapping of 95% CIs with noise only in three thalamic VOIs, showing that perfusion MRI with a 2 mg/kg dose ferumoxytol is feasible. The higher dose ferumoxytol causing stronger signal drop resulted in improved CNR, thus better visual discrimination capability. In theory, higher CNR may allow higher image resolution or better differentiation of normal and pathologic structures, which may be useful to detect subtle rCBV differences. We found that 2 mg/kg for DSC imaging has the drawback of providing mildly different rCBV values compared to gadoteridol. This difference likely arises from the assumption that the transverse relaxation rate difference (DR2*) is linearly proportional with the tissue contrast agent concentration. The shape of the first-pass curve, blooming of larger vessels during first pass, and the postprocessing algorithm may also contribute to these differences. To overcome the issues related to dynamic imaging, high-resolution steady-state CBV mapping may be considered, which requires higher ferumoxytol doses, but no bolus administration. 13 We added a subjective method to assess the quality of the CBV maps, using two independent readers, blinded to contrast agent information. There was mild improvement in the visual conspicuity of the putamen with 1 mg/kg ferumoxytol, and marked improvement with 2 mg/kg ferumoxytol compared to gadolinium, indicating the advantage of using a higher ferumoxytol dose. Clinical radiology practices often evaluate CBV maps solely based on color maps without measuring actual CBV values, therefore increased visual conspicuity is a practical clinical value.
Possible limitations of the study were: 1) that normalappearing brain areas were analyzed in patients with known focal brain pathologies. To minimize errors, VOIs were carefully visually analyzed on T 2 -weighted images and pathological areas were excluded. 2) Subjects in this study may have undergone various therapies (including chemotherapy and radiation) prior to imaging; therefore, even normalappearing brain may have had altered blood volume. Since paired data were used during analysis for this contrast agent comparison study, the various treatment-related changes likely affected the compared variables evenly.
3) The automatic segmentation of deep gray matter structures was based on MPRAGE images. Blooming artifact from adjacent larger vessels on DSC images may have affected the value measured in the VOI. This was most prominently observed in the posterior thalamus, and likely affected the scans with ferumoxytol and gadolinium similarly. 4) Another limitation is that only a single TR, TE, and flip angle combination was available in this study, which is very common in clinical practice.
Currently, the FDA recommends against rapid administration of ferumoxytol. While the prior prescribing information of Feraheme allowed rapid bolus injection of the total 510 mg of ferumoxytol as fast as in 17 seconds, since March 2015 the prescribing information recommends slow infusion of the total dose over 15 minutes. This change was made to mitigate the potential risk and morbidity of hypersensitivity reactions. 32 When used off-label for imaging, the diagnostic information gained through bolus injection of 1 or 2 mg/kg, which is a small fraction of the therapeutic dose, likely overweigh the potential small increased risk of hypersensitivity.
In conclusion, this study demonstrates that 1 mg/kg (about 75 mg Fe) ferumoxytol bolus is similar to the standard dose of gadoteridol (>1000 mg of Gd) for DSC imaging. This dose likely provides the best comparison of literature data with perfusion MRI using standard gadolinium. Also, 1 mg/kg is likely safer than bolus injection of larger doses, although there are currently no data to support an increased risk of adverse reactions due to small bolus injected doses. Still, the improved CNR and better subjective visualization of structures may justify higher doses, such as 2 mg/kg. Ferumoxytol is a viable option for MRI, including DSC perfusion, in the event of contraindication of currently approved contrast agents due to impaired renal function, or a concern for potential long-term effects of gadolinium tissue deposition.
